| Business Summary | | Aphton
Corporation
is
a
biopharmaceutical
company
in
late-stage
clinical
trials
for
four
cancer
indications.
Aphton
is
developing
products
using
its
vaccine-like
technology
to
block
hormones
that
play
key
roles
in
cancer
and
other
disorders
of
the
gastrointestinal
and
reproductive
systems.
The
Company
is
initially
targeting
large
cancer
markets
where
there
are
no
standards
of
care
available.
The
Company's
lead
product,
an
anti-gastrin
immunogen,
is
in
two
separate
Phase
III
clinical
trials
for
pancreatic
cancer
in
the
United
States
and
Europe;
in
a
pivotal
trial
for
chemo-refractory
colorectal
cancer;
and
in
a
Phase
II
study
in
gastric
(stomach)
cancer.
Aphton
has
strategic
alliances
with
Aventis
Pasteur,
GlaxoSmithKline,
Schering
Plough
Animal
Health,
and
the
World
Health
Organization
(WHO). | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | APHT
is
a
biopharmaceutical
company
developing
products
using
its
innovative
vaccine-like
technology
for
neutralizing
hormones
that
participate
in
gastrointestinal
system
and
reproductive
system
cancer
and
non-cancer
diseases;
and
the
prevention
of
pregnancy.
For
the
comparable
five
months
ended
6/30/01,
revenues
were
$0.
Net
loss
rose
80%
to
$9.9
million.
Results
reflect
the
absence
of
contract
revenues,
and
increases
in
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000
Compensation | | Pay | Exer | |
| Philip Gevas, 67 Chairman,
CEO and Pres | $400K | -- | William Hasler, 59 Vice
Chairman and Co-CEO | 180K | $111K | Dov Michaeli, Ph.D., 62 Sr.
VP, Director of Medical Science and CMO | 210K | 2.2M | Douglas Eayrs VP-Fin. | -- | -- | Donald Henderson VP
and Managing Director, finance and administration | -- | -- | Dollar amounts are as of 31-Jan-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|